PureTech Health PLC
LSE:PRTC
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
140.4
237.5
|
Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one PRTC stock under the Base Case scenario is 38.55 GBX. Compared to the current market price of 172.2 GBX, PureTech Health PLC is Overvalued by 78%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
PureTech Health PLC
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for PRTC cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
PureTech Health PLC
Balance Sheet Decomposition
PureTech Health PLC
Current Assets | 508.8m |
Cash & Short-Term Investments | 502.1m |
Receivables | 2.1m |
Other Current Assets | 4.7m |
Non-Current Assets | 71.1m |
Long-Term Investments | 29m |
PP&E | 17.3m |
Intangibles | 906k |
Other Non-Current Assets | 23.9m |
Current Liabilities | 138.3m |
Accounts Payable | 8.1m |
Accrued Liabilities | 23.3m |
Other Current Liabilities | 106.9m |
Non-Current Liabilities | 125.8m |
Long-Term Debt | 16.4m |
Other Non-Current Liabilities | 109.3m |
Earnings Waterfall
PureTech Health PLC
Revenue
|
468k
USD
|
Operating Expenses
|
-136.9m
USD
|
Operating Income
|
-136.4m
USD
|
Other Expenses
|
54m
USD
|
Net Income
|
-82.5m
USD
|
Free Cash Flow Analysis
PureTech Health PLC
USD | |
Free Cash Flow | USD |
PRTC Profitability Score
Profitability Due Diligence
PureTech Health PLC's profitability score is 17/100. The higher the profitability score, the more profitable the company is.
Score
PureTech Health PLC's profitability score is 17/100. The higher the profitability score, the more profitable the company is.
PRTC Solvency Score
Solvency Due Diligence
PureTech Health PLC's solvency score is 51/100. The higher the solvency score, the more solvent the company is.
Score
PureTech Health PLC's solvency score is 51/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PRTC Price Targets Summary
PureTech Health PLC
According to Wall Street analysts, the average 1-year price target for PRTC is 559.98 GBX with a low forecast of 459.55 GBX and a high forecast of 675.15 GBX.
Dividends
Current shareholder yield for PRTC is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
PureTech Health Plc engages in the provision of differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. The company is headquartered in Boston, Massachusetts and currently employs 66 full-time employees. The company went IPO on 2015-06-19. The firm is engaged in discovering, developing and commercializing medicines for diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. The firm's wholly owned pipeline consists of six therapeutic candidates including LYT-100 (deupirfenidone), LYT-200, LYT-210, LYT-300 (oral allopregnanolone), LYT-500, and LYT-503/IMB-150. Its segments include Internal, Controlled Founded Entity, Non-Controlled Founded Entities, and Parent Company and Other. Its Internal segment is advancing wholly owned programs designed to harness immunological, fibrotic and lymphatic system mechanisms. These classes of immunomodulatory drugs are designed to treat serious diseases, including lung dysfunction, immuno-oncology, lymphatic, neurological and neuropsychological disorders.
Contact
IPO
Employees
Officers
The intrinsic value of one PRTC stock under the Base Case scenario is 38.55 GBX.
Compared to the current market price of 172.2 GBX, PureTech Health PLC is Overvalued by 78%.